|
1
|
Yung KW, Yung TT, Chung CY, Tong GT, Liu
Y, Henderson J, Welbeck D and Oseni S: Principles of cancer
staging. Asian Pac J Surg Oncol. 1:1–16. 2015.
|
|
2
|
Ghoneum M, Felo N, Nwaogu OM, Fayanju IY,
Jeffe JA and Margenthaler DB: Clinical trials in Surgical Oncology.
Asian Pac J Surg Oncol. 1:73–82. 2015.
|
|
3
|
Mellotte G, Maher V, Devitt PG, Shin VY
and Leung CP: Minimally invasive Surgical Oncology: State of the
art. Asian Pac J Surg Oncol. 1:101–112. 2015.
|
|
4
|
Guarneri A, Franco P, Trino E, Campion D,
Faletti R, Mirabella S, Gaia S, Ragona R, Diotallevi M, Saracco G,
et al: Stereotactic ablative radiotherapy in the treatment of
hepatocellular carcinoma >3 cm. Med Oncol. 33:1042016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ippolito D, Trattenero C, Franzesi C
Talei, Casiraghi A, Lombardi S, Vacirca F, Corso R and Sironi S:
Dynamic contrast-enhanced magnetic resonance imaging with
gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for
quantitative assessment of vascular effects on
hepatocellular-carcinoma lesions treated by transarterial
chemoembolization or radiofrequency ablation. J Comput Assist
Tomogr. 40:692–700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang
B, Wang Y, Ye S and Ren Z: Transarterial chemoembolization versus
radiofrequency ablation for recurrent hepatocellular carcinoma
after resection within barcelona clinic liver cancer stage 0/A: A
retrospective comparative study. J Vasc Interv Radiol.
27:1829–1836. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spolverato G, Vitale A, Bagante F,
Connolly R and Pawlik TM: Liver resection for breast cancer liver
metastases: A cost-utility analysis. Ann Surg. 265:792–799. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sadot E, Lee SY, Sofocleous CT, Solomon
SB, Gönen M, Kingham T Peter, Allen PJ, DeMatteo RP, Jarnagin WR,
Hudis CA, et al: Hepatic resection or ablation for isolated breast
cancer liver metastasis: A case-control study with comparison to
medically treated patients. Ann Surg. 264:147–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Lai L, Liu S, Zhou C, Wu C, Huang
M and Lin Q: Targeting HIF-1α and VEGF by lentivirus-mediated RNA
interference reduces liver tumor cells migration and invasion under
hypoxic conditions. Neoplasma. 63:934–940. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma R, Feng Y, Lin S, Chen J, Lin H, Liang
X, Zheng H and Cai X: Mechanisms involved in breast cancer liver
metastasis. J Transl Med. 13:642015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee R, Yeung AW, Hong SE, Brose MS and
Michels DL: Principles of medical oncology. Asian Pac J Surg Oncol.
1:39–46. 2015.
|
|
12
|
Zheng YF, Tan LK, Tan BH, Sterling H and
Kane R: Principles of surgical oncology. Asian Pac J Surg Oncol.
1:17–26. 2015.
|
|
13
|
Dai WC and Cheung TT: Strategic overview
on the best treatment option for intrahepaitc hepatocellular
carcinoma recurrence. Expert Rev Anticancer Ther. 16:1063–1072.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pecorelli A, Lenzi B, Gramenzi A, Garuti
F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL,
Di Marco M, et al: Italian Liver Cancer (ITA.LI.CA) group. Curative
therapies are superior to standard of care (transarterial
chemoembolization) for intermediate stage hepatocellular carcinoma.
Liver Int. Aug 27–2016.(Epub ahead of print). doi:
10.1111/liv.13242.
|
|
15
|
Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D,
Wang K, Xia Y and Shen F: Retrospective analysis of transarterial
chemoembolization and sorafenib in Chinese patients with
unresectable and recurrent hepatocellular carcinoma. Oncotarget.
7:83806–83816. 2016.PubMed/NCBI
|
|
16
|
Ludwig JM, Zhang D, Xing M and Kim HS:
Meta-analysis: adjusted indirect comparison of drug-eluting bead
transarterial chemoembolization versus 90Y-radioembolization for
hepatocellular carcinoma. Eur Radiol. Aug 25–2016.(Epub ahead of
print).
|
|
17
|
Choi JW, Kim HC, Lee JH, Yu SJ, Kim YJ,
Yoon JH, Jae HJ, Hur S, Lee M and Chung JW: Transarterial
chemoembolization of hepatocellular carcinoma with segmental portal
vein tumour thrombus. Eur Radiol. Aug 11–2016.(Epub ahead of
print).
|
|
18
|
Hou YF, Wei YG, Yang JY, Wen TF, Xu MQ,
Yan LN and Li B: Combined hepatectomy and radiofrequency ablation
versus TACE in improving survival of patients with unresectable
BCLC stage B HCC. Hepatobiliary Pancreat Dis Int. 15:378–385. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ha Y, Lee D, Shim JH, Lim YS, Lee HC,
Chung YH, Lee YS, Park SR, Ryu MH, Ryoo BY, et al: Role of
transarterial chemoembolization in relation with sorafenib for
patients with advanced hepatocellular carcinoma. Oncotarget.
7:74303–74313. 2016.PubMed/NCBI
|
|
20
|
Cahill T, Chen XL, Lee JW, Weiss M, Chang
VT and Cella D: Principles of radiofrequency ablation for cancer.
Asian Pac J Surg Oncol. 1:47–58. 2015.
|
|
21
|
Wu J, Lin S, Wu W, Yan K, Dai Q and Chen
M: Clinical application of ultrasound-guided radiofrequency
ablation for primary hepatocellular carcinoma near the liver
surface. Zhonghua Zhong Liu Za Zhi. 37:933–937. 2015.(In Chinese).
PubMed/NCBI
|
|
22
|
Nitta H, Nakagawa S, Kaida T, Arima K,
Higashi T, Taki K, Okabe H, Hayashi H, Hashimoto D, Chikamoto A, et
al: Pre-treatment double- or triple-positive tumor markers are
predictive of a poor outcome for patients undergoing radiofrequency
ablation for hepatocellular carcinoma. Surg Today. 47:375–384.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu L, Rong Y, Wang W, Lian H, Gan W, Yan
X, Li X and Guo H: Percutaneous radiofrequency ablation with
contrast-enhanced ultrasonography for solitary and sporadic renal
cell carcinoma in patients with autosomal dominant polycystic
kidney disease. World J Surg Oncol. 14:1932016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seror O, N' Kontchou G, Nault JC, Rabahi
Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M,
Trinchet JC, et al: Hepatocellular carcinoma within milan criteria:
No-touch multibipolar radiofrequency ablation for
treatment-long-term results. Radiology. 280:9812016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang C, Shen J, Feng W, Bao Y, Dong X, Dai
Y, Zheng Y and Zhang J: Combination therapy of radiofrequency
ablation and transarterial chemoembolization for unresectable
hepatocellular carcinoma: A retrospective study. Medicine
(Baltimore). 95:e37542016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi F, Zhang L, Li S, Lin CJ, Shen LJ, Li
CF, Jie M, Li ZW and Wu PH: Chemolipiodolization with or without
embolization in transcatheter arterial chemoembolization combined
with radiofrequency ablation for hepatocellular
carcinoma-propensity score matching analysis. Oncotarget.
7:31311–31321. 2016. View Article : Google Scholar : PubMed/NCBI
|
